Jonathan D. Mahnken, Ph.D.

1. Mahnken JD, Chan W, Freeman DH, Freeman JL: “Reducing the Effects of Lead-Time Bias, Length Bias, and Over-Detection in Evaluating Screening Mammography: A Censored Bivariate Data Approach.”  Statistical Methods in Medical Research, 17:643-663, 2008.

2. Mahnken JD, Mayo MS, Nudo RJ: “A Decision Algorithm for Translating Preclinical Trial Results to Enhance Recovery after Stroke.”  Journal of Biopharmaceutical Statistics, 19(1):204-216, 2009.  PMCID: PMC2700836.

3. Ellerbeck EF, Mahnken JD, Cupertino AP, Sanderson Cox L, Greiner KA, Mussulman LM,  Nazir N, Shireman T, Resnicow K, Ahluwalia JS: “Effect of Varying Levels of Disease Management on Smoking Cessation: A Randomized Trial.”  Annals of Internal Medicine, 150(7):437-446, 2009.  PMCID: PMC2825176.

4. Mahnken JD: “Power and Sample Size Calculations for Models from Unknown Distributions Using Quasi-likelihood Methods.”  Statistics in Biopharmaceutical Research.  1(3):328-336, 2009.

5. Mayo MS, Mahnken JD, Soong S: “Optimal Designs for Two-Arm, Phase II Clinical Trial Design with Multiple Constraints.”  Journal of Biopharmaceutical Statistics.  20(1):106-124, 2010.

6. Ambrosius W, Mahnken JD: “Power for Studies with Random Group Sizes.”  Statistics in Medicine.  29:1137-1144, 2010.  PMCID: PMC2936967.

7. Mahnken JD, Wick JA, Gajewski BJ, Mayo MS: “A Study Design with Conditional, Serially Assessed Co-primary Endpoints: An Application to a Single-arm, Pilot Non-Hodgkin’s Lymphoma Trial.”  Drug Development Research.  71:395-403, 2010.  Invited.

8. Wetmore JB, Santos P, Mahnken JD, Krebill R, Menard R, Gutta H, Quarles LD: “FGF23 Levels Are Associated with Degree of Dynamic Calcium-mediated Suppression of PTH in ESRD.”  Journal of Clinical Endocrinology & Metabolism.  96(1):E57-E64, 2011.

9. Wetmore JB, Mahnken JD, Mukhopadhyay P, Hou Q, Ellerbeck EF, Rigler SK, Spertus JA, Shireman TI: “Geographic Variation in Cardioprotective Antihypertensive Medication Usage in Dialysis Patients.”  American Journal of Kidney Diseases.  58(1):73-83, 2011.

10. Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA, Hou Q, Shireman TI: “The Prevalence of and Factors Associated with Chronic Atrial Fibrillation in Medicare/Medicaid-eligible Dialysis Patients.”  Kidney International.  81: 469-476, 2012.  PMCID: In process.

11. Wetmore JB, Mahnken JD, Mukhopadhyay P, Hou Q, Ellerbeck EF, Rigler SK,  Spertus JA, Shireman TI: “Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients.”  Journal of General Internal Medicine.  27(11):1475-1482, 2012.

12. Mahnken JD, He J, Yeh HW, Nazir N, Jianas LL, Engelman KK: “Survival Analysis Applied to Proportion Data: Comparing Mammography Visits in High and Low Repeat Rate Facilities.”  Health Services and Outcomes Research Methodology.  13(1):68-83, 2013.

13. Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Hou Q, Shireman TI: “Association of Race with Cumulative Exposure to Statins in Dialysis.”  American Journal of Nephrology.  36:90-96, 2012.

14. Wetmore JB, Ellerbeck EF, Mahnken JD, Phadnis M, Rigler SK, Mukhopadhyay P, Spertus JA, Zhou X, Hou Q, Shireman TI: “Atrial Fibrillation and Risk of Stroke in Dialysis Patients.”  Annals of Epidemiology.  (Accepted.)

15. Rigler SK, Shireman TI, Cook-Wiens G, Ellerbeck EF, Whittle J, Mehr D, Mahnken JD: “Fracture Risk among Nursing Home Residents Initiating Antipsychotic Medications.”  Journal of the American Geriatric Society.  (Accepted.)